Compare
Celularity Inc vs Zomedica Corp. vs CASI Pharmaceuticals, Inc. vs Bioharvest Sciences Inc.
| Latest fiscal year | Celularity Inc CELU | Zomedica Corp. ZOMDF | CASI Pharmaceuticals, Inc. CASIF | Bioharvest Sciences Inc. BHST |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $26.55M | $32.03M | $20.71M | $34.51M |
| Revenue growth (YoY) | -51.0% | +17.4% | -27.4% | +37.0% |
| Gross margin | 24.4% (computed) | 67.7% | 48.6% | 59.3% (computed) |
| Operating margin | -230.9% | -263.4% | -217.3% | -16.2% |
| Net margin | -345.4% | -255.6% | -232.0% | -32.3% |
| Net income | -$91.72M | -$81.86M | -$48.06M | -$11.13M |
| EPS (Diluted) | -$3.59 | -$0.08 | -$2.59 | n/a |
| Operating cash flow | -$13.25M | -$17.65M | -$20.75M | -$7.23M |
| Free cash flow | n/a | -$18.22M | -$20.77M | -$9.58M |
| Cash & equivalents | $6.17M | $9.02M | $5.63M | $23.02M |
| Total assets | $107.33M | $127.04M | $25.65M | n/a |
| Total liabilities | $145.39M | $11.64M | $62.93M | n/a |
| Shareholders' equity | -$38.06M | $115.40M | -$37.28M | $25.45M |
| Return on year-end equity | n/a | -70.9% | n/a | -43.8% |
| Shares outstanding | 28.84M | 979.95M | 20.56M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Celularity Inc | Zomedica Corp. | CASI Pharmaceuticals, Inc. | Bioharvest Sciences Inc. |
|---|---|---|---|---|
| Latest | $26.55M Ended 2025-12-31 | $32.03M Ended 2025-12-31 | $20.71M Ended 2025-12-31 | $34.51M Ended 2025-12-31 |
| 1 year earlier | $54.22M Ended 2024-12-31 | $27.29M Ended 2024-12-31 | $28.54M Ended 2024-12-31 | $25.19M Ended 2024-12-31 |
| 2 years earlier | $22.77M Ended 2023-12-31 | $25.19M Ended 2023-12-31 | $33.88M Ended 2023-12-31 | $12.67M Ended 2023-12-31 |
| 3 years earlier | $17.98M Ended 2022-12-31 | $18.93M Ended 2022-12-31 | $43.11M Ended 2022-12-31 | n/a |
| 4 years earlier | $21.34M Ended 2021-12-31 | $4.13M Ended 2021-12-31 | $30.17M Ended 2021-12-31 | n/a |